Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04516447 · ClinicalTrials.gov registry record · Phase 1
A Study of ZN-c3 in Patients With Ovarian Cancer
A Phase 1 study of Solid Tumor and Fallopian Tube Cancer, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 140
- Enrollment target
- 20
- Study locations
NCT04516447: Recruiting Phase 1 study of Solid Tumor and Fallopian Tube Cancer, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
NCT04516447 is a Phase 1 study of Solid Tumor and Fallopian Tube Cancer that is actively recruiting participants, run by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals. The registered enrollment target is 140 participants, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (37% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04516447, a Phase 1 study of Solid Tumor and Fallopian Tube Cancer, is actively recruiting participants, sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 140 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
Primary Outcome
Incidence and severity of adverse events (AEs)
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Paclitaxel
- DRUG Gemcitabine
- DRUG ZN-c3
- DRUG Pegylated liposomal doxorubicin
Study Locations (20)
Other
- Site 1001 - Banja Luka
- Site 1002 - Sarajevo
- Site 1003 - Tuzla
- Site 1202 - Panagyurishte
- Site 1201 - Sofia
- Site 1401 - Tbilisi
Queensland
- Site 2707 - South Brisbane
- Site 2708 - Sunshine Coast
Victoria
- Site 2716 - Melbourne
- Site 2706 - Melbourne
Colorado
- Site 0264 - Aurora
Massachusetts
- Site 0104 - Boston
Missouri
- Site 0111 - St Louis
New York
- Site 0173 - New York
North Carolina
- Site 0259 - Durham
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 140 participants |
| Start Date | 2020-10-26 |
| Est. Completion | 2027-02-28 |
| Phase | Phase 1 |
What NCT04516447 shows while recruiting
NCT04516447 is an interventional study that assigns participants to a tested intervention. The registered 140 participants enrollment target is mid-sized for trials with a published cap, below the 221-participant average among 196 other Solid Tumor trials with a reported enrollment target (37% lower).
The record links to 4 conditions, with Solid Tumor appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT04516447 names 20 study sites across 13 states, led by Other, Queensland, Victoria.
Frequently Asked Questions
What is clinical trial NCT04516447 about?
NCT04516447 is a clinical study titled "A Study of ZN-c3 in Patients With Ovarian Cancer". This is a Phase 1b open-label, multicenter study, evaluating the safety, tolerability, preliminary clinical activity, pharmacokinetics (PK), and pharmacodynamics of ZN-c3 in combination with other drugs.
What is the current status of trial NCT04516447?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 140 participants. The study started on 2020-10-26. Estimated completion is 2027-02-28.
What conditions does trial NCT04516447 study?
This clinical trial studies the following conditions: Solid Tumor, Fallopian Tube Cancer, Epithelial Ovarian Cancer, Peritoneal Cancer.
What interventions are being tested in trial NCT04516447?
The interventions under investigation include: Carboplatin (DRUG), Paclitaxel (DRUG), Gemcitabine (DRUG), ZN-c3 (DRUG), Pegylated liposomal doxorubicin (DRUG).
Who is sponsoring clinical trial NCT04516447?
This trial is sponsored by K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04516447 being conducted?
This trial has 20 study locations across Colorado, Massachusetts, Missouri, New York, North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Solid Tumor
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04516447's enrollment target sits among peer trials
140 63rd of 196 higher than 132 of 196 other Solid Tumor trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Solid Tumor trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study to Evaluate Safety, Efficacy, and Pharmacokinetics in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
-
A Phase I Study of ROSE12 Alone and in Combination With Other Anti-tumor Agents in Patients With Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of Tolododekin Alfa (ANK-101) in Advanced Solid Tumors
RECRUITING · Phase 1
-
Concurrent Azeliragon With Craniospinal Irradiation
RECRUITING · Phase 1
-
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
RECRUITING · Phase 1
-
A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01419561 · 140 participants · Phase 2
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
- NCT01624805 · 140 participants · Phase 2
Methylprednisolone, Horse Anti-Thymocyte Globulin, Cyclosporine, Filgrastim, and/or Pegfilgrastim or Pegfilgrastim Biosimilar in Treating Patients With Aplastic Anemia or Low or Intermediate-Risk Myelodysplastic Syndrome
- NCT02369770 · 140 participants · NA
Sensory-Motor Rehabilitation Post Stroke
- NCT02455193 · 140 participants · NA
Neuronal Effects of Exercise in Schizophrenia
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI